Drug Trial Radar · NCT02558231
The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed Pulmonary Arterial Hypertension
Last checked: Nov 19, 2026Latest source record: Mar 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
247
Actual
Start
May 1, 2016
Primary completion
Aug 29, 2019
Study completion Apr 20, 2020
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Sep 23, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this clinical trial is to compare the efficacy and safety of an initial triple oral treatment regimen (macitentan, tadalafil, selexipag) versus an initial dual oral treatment regimen (macitentan, tadalafil, placebo) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension.
Conditions
- Pulmonary Arterial Hypertension
Interventions
MacitentanDrug
Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
TadalafilDrug
Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
SelexipagDrug
Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 26 in Pulmonary Vascular Resistance (PVR)Time frame: Baseline, Week 26
Locations
58 sites in 15 countries. Site status is shown where the registry gives one.
Arizona Pulmonary Specialists, LTD
Phoenix, Arizona
UCSD Health Sciences
La Jolla, California
UCLA Medical Center
Los Angeles, California
Mayo Clinic Jacksonville
Jacksonville, Florida
Cleveland Clinic Florida
Weston, Florida
Piedmont Pulmonary and Critical Care Research
Atlanta, Georgia
Northwestern University
Chicago, Illinois
University of Iowa Hospitals & Clinics
Iowa City, Iowa
Kentuckiana Pulmonary Associates
Louisville, Kentucky
LSU Health Sciences Center
New Orleans, Louisiana
Johns Hopkins School of Medicine
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
Washington University School of Medicine
Saint Louis, Michigan
University of New Mexico Hospital
Albuquerque, New Mexico
The Christ Hospital
Cincinnati, Ohio
Allegheny General Hospital of Research
Pittsburgh, Pennsylvania
UPMC Presbyterian
Pittsburgh, Pennsylvania
University of Texas Southwestern Medical Center
Dallas, Texas
Houston Methodist Hospital
Houston, Texas
Royal Prince Albert Hospital
Camperdown, New South Wales, Australia
St. Vincents Hospital Sydney
Darlinghurst, New South Wales, Australia
LKH -Universität Klinkum Graz
Graz, Austria
Krankenhaus der Elisabethinen Linz
Linz, Austria
AKH Wien
Vienna, Austria
Hôpital Erasme
Brussels, Belgium
UZ Leuven - Campus Gasthuisberg
Leuven, Belgium
University of Calgary
Calgary, Canada
University of Ottawa Heart Institute
Ottawa, Canada
Vancouver General Hospital
Vancouver, British Columbia, Canada
London Health Sciences Centre - Victoria Hospital
London, Ontario, Canada
University of Toronto
Toronto, Ontario, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Institut Universitaire de Cardiologie et de Pneumologie de Québec
Québec, Quebec, Canada
Aarhus University Hospital Skejby
Aarhus, Denmark
Rigshospitalet Copenhagen
Copenhagen, Denmark
CHU de Bicêtre
Le Kremlin-Bicêtre, France
Universitätsklinikum Köln
Cologne, Germany
Unversitätsklinikum Carl Gustav Carus
Dresden, Germany
Universitätsklinikum Giessen
Giessen, Germany
Showing 40 of 58 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.